Nuclera

Nuclera, founded in 2013 by PhD students at the University of Cambridge, has positioned itself as a transformative player in the biotechnology, life sciences, and pharmaceutical industries. With its headquarters in the United Kingdom and a burgeoning presence in Boston, MA, the company employs over 100 professionals dedicated to advancing protein science.

Capitalizing on its pioneering eProtein Discovery™ technology, Nuclera revolutionizes how researchers access and screen proteins through innovative, cell-free expression systems and digital microfluidics. This system enables rapid, in-house multiplex protein screening, even for challenging membrane proteins, which accelerates scientific discovery and breakthroughs in human health.

In its latest funding round on 01 January 2026, Nuclera secured a $12.00M Series C investment led by Elevage Medical Technologies, with participation from British Business Bank, Jonathan Milner, and GK Goh Financial Services. This investment underscores strong confidence in Nuclera's potential to make protein access routine and propel scientific innovation forward.